On June 18th - 21^th 2022, the Vietnam annual academic conference of Luotai Panax notoginseng series products was grandly held in Viet Halong Bay. Prof. Nguyen Minh Thong, the president of Vietnam Stroke Association, was invited to be the chairman of the conference. Prof. Mai Duy Dong, director of the Stroke Center of Bac Mai Hospital in Hanoi, and more than 100 well-known experts in the field of stroke from more than 60 provincial and municipal hospitals in 33 provinces in Vietnam were also invited. The experts and scholars gathered together to explore new trends in diagnostic and treatment of stroke patients in the post-epidemic era.

At the beginning of the meeting, Mr. Guo Hai, deputy general manager of overseas division of KPC Pharmaceuticals, Inc., delivered a video speech to express his respect to attendees, and paid tribute to the hard work of every anti-epidemic personnel in Vietnam. He also expressed his warmest welcome and gratitude to the experts and scholars attended the meeting, and thanked them for their support and recognition of KPC Pharmaceuticals, Inc. and Luotai series products in the past two decades. In addition, Mr. Guo also introduced the market conditions of KPC’s Luotai panax notoginseng series products in domestic market in the past two years, briefed KPC's future development strategy for panax notoginseng industry chain, strengthened confidence of experts and scholars toward Luotai.

In this conference, Professor Mai Duc Ton, director of the Department of Neurology of Bai Mai Hospital in Vietnam, led the participants to discuss the management of stroke patients in the post-epidemic era and the new progress of professional knowledge in the field of stroke. At the meeting, Professor Pham Din Dai of Vietnam 103 Military Hospital shared classic cases of successful stroke treatment with integrated traditional Chinese and western medicine in recent years with the participants, allowing the participants to appreciate that traditional Chinese medicine is now an indispensable medicine in stroke rehabilitation treatment. Professor also shared experiences of using our KPC's Luotai series products in stroke patients. Finally, the multi-center clinical trial results of Luotai series products in Vietnam were announced at the meeting. The clinical trial further confirmed that the sequential therapy of Luotai lyophilized powder injection + oral Luotai soft capsule is effective in the treatment of ischemia, laid a solid foundation for Vietnamese doctors to use Luotai series products.

Adhering to the mission of "Green KPC, Benefiting the Society", KPC continues to benefit the health of people around the world with quality. At present, Luotai series have obtained marketing licenses in Vietnam, Myanmar, Cambodia, Mongolia, Indonesia, Malaysia, Singapore, Thailand, Uzbekistan, Tanzania, Uganda, Cameroon, Cote d’Ivoire, Chad and Congo, etc. Luotai series have become another historic breakthrough in China's traditional Chinese medicine pharmaceutical industry, further promoting the international wave of the promotion of the medicinal value of panax notoginseng.